STAT+: Sarepta names Michael Severino, former Tessera CEO, as new chief executive

STAT PlusBiotech Sarepta names Michael Severino, former Tessera CEO, as new chief executive Sarepta has seen its share price crater and faces looming competition Manage alerts for this article Email this article Share this article By Andrew JosephJuly 27, 2026 Europe Correspondent Andrew Joseph[email protected]Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. Sarepta Therapeutics, the bruised maker of Duchenne muscular dystrophy treatments, on Monday named Michael Severino, formerly the CEO of Tessera Therapeutics, as its new chief executive, starting Tuesday. Severino is replacing Doug Ingram, who announced earlier this year that he planned to retire after leading the biotech for nearly a decade. During his tenure, the company got three Duchenne treatments approved, but has faced ongoing questions about how effective they are and run into regulatory scrutiny over the safety of its gene therapy. Advertisement The company’s share price has tanked from where it was at the beginning of 2025. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, rare disease, STAT+ Submit a correction requestReprints Andrew Joseph Europe Correspondent Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended Breaking News July 27, 2026 STAT Plus: Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug Biotech July 27, 2026 STAT Plus: RA Capital backs upstart rival to Ultragenyx and Ionis in rare brain disease Advertisement Biotech July 27, 2026 STAT Plus: Argenx to buy Forte Biosciences for $2.2B Health July 24, 2026 FDA advisory panel narrowly rejects compounding of one peptide, backs two others The Readout July 24, 2026 STAT Plus: Fatal gene-editing trial in China raises ethics and oversight questions Subscriber Picks